Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study

Trial Profile

Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 12 May 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 May 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 19 Feb 2016 Planned End Date changed from 1 Jun 2015 to 1 Dec 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top